[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529950":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":59,"collaborators":62,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":10,"enrollmentInfo":89,"targetDuration":10,"studyType":92,"phases":10,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Proton group",null,"Patients with grade 2 and 3 IDHmt glioma treated with proton therapy in Holland PTC, Maastro Clinic and UMC Groningen.",[13],"Radiation: proton therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Photon group","Patients with grade 2 and 3 IDHmt glioma treated with photon therapy in Erasmus MC, Haaglanden MC, LUMC, Amsterdam UMC locatie VUmc Site, Verbeeten Institute, Maastro Clinic, UMC Groningen, and Leuven University Hospital.",[18],"Radiation: photon therapy",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"RADIATION","proton therapy","Radiotherapy delivered with protons",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"photon therapy","Radiotherapy delivered with photons",[15],[30],{"name":31,"affiliation":32,"role":33},"Alejandra Mendez Romero, MD PhD","Assitant Professor, Radiation Oncologist","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Steven HJ Nagtegaal, MD PhD","CONTACT","+31(0)107042249","s.nagtegaal@erasmusmc.nl",{"name":31,"role":37,"phone":41,"phoneExt":10,"email":42},"+31(0)107035829","a.mendezromero@erasmusmc.nl",[44],{"facility":45,"status":46,"city":47,"state":10,"zip":10,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Erasmus MC","RECRUITING","Rotterdam","Netherlands","NL",{"type":51,"coordinates":52},"Point",[53,54],4.47917,51.9225,{"lat":54,"lon":53},[57],{"name":58,"role":37,"phone":10,"phoneExt":10,"email":10},"Steven Nagtegaal, MD PhD",{"type":33,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Alejandra Mendez Romero","Principal Investigator",[63,65,67,70,72,74,76,78],{"name":64,"class":6},"Medical Center Haaglanden",{"name":66,"class":6},"Leiden University Medical Center",{"name":68,"class":69},"HollandPTC","INDUSTRY",{"name":71,"class":6},"Institute Verbeeten",{"name":73,"class":6},"Universitaire Ziekenhuizen KU Leuven",{"name":75,"class":6},"University Medical Center Groningen",{"name":77,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"name":79,"class":6},"Maastro Clinic, The Netherlands","100529950","short-term-outcomes-after-proton-and-photon-radiotherapy-for-idh-mutated-grade-2-and-3-gliomas-100529950",false,"NCT06180434","Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas","SOPRANO","Inclusion Criteria:\n\n* Histopathologically confirmed WHO grade 2 or grade WHO 3 IDHmt glioma\n* Treatment with radiotherapy delivered between 1 of January 2018 and completed before or on the 30th of June 2022\n* Treatment with chemotherapy delivered after radiotherapy (PCV or Temozolomide)\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Prior cranial radiotherapy\n* Contra-indication for MRI imaging\n* Chemotherapy delivered before radiotherapy\n* Dose and fractionation other that standard dose (50.4 Gy in 28 fractions for Grade 2 and 59.5 Gy in 33 fractions for Grade 3)\n* Combination photon and proton therapy\n* Patient has previously opted-out of the use of their data for research","ALL","18 Years",{"count":90,"type":91},320,"ESTIMATED","OBSERVATIONAL","Rationale:\n\nProton beam therapy has recently become available for the treatment of patients with WHO grade 2 and 3 IDH mutated (IDHmt) glioma in the Netherlands. The dose distributions associated with proton therapy have substantially reduced the volume of the normal brain irradiated with low and intermediate radiotherapy doses. Whether this impacts rates of progressive disease or safety issues and how this compares with a similar population treated with photon therapy is currently unknown.\n\nObjective:\n\nTo investigate short term outcomes after proton and photon radiotherapy for grade 2 and 3 IDHmt glioma.",[95,96],"Glioma","Radiotherapy; Complications",[98,99,100],"Neuro-oncology","Proton therapy","Photon therapy","2024-10-09",{"date":103,"type":104},"2024-10-15","ACTUAL",{"date":106,"type":104},"2024-05-01",{"date":108,"type":91},"2025-11-01",{"name":5,"class":6},1]